HIND — Vyome Holdings, Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1427570 ·
Last close
$1.54
Market Cap
$10.84M
52W High
$5.88
52W Low
$1.49
ADV30
11,018
Next earnings
—
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 26,955 11,658 -862,566 -685,556 9,176,362 7,887,510 1,864,656
Mar 2026 31,591 16,645 -1,129,940 -962,910 10,185,446 8,795,783 2,144,125
Dec 2025 36,551 22,066 -1,355,074 -1,063,974 6,497,177 4,982,333 2,735,160
Sep 2025 34,627 18,050 -868,777 -8,595,300 7,045,396 5,707,012 3,126,936

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,578,745
Investing CF
$0
Financing CF
$13,149,591
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.43
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-89,212,041
Inventory
—
Receivables
$152,665
ST Investments
—
EBIT TTM
$-11,538,466
Pretax Income TTM
$-11,580,184
Interest Exp TTM
$41,718
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$153,096
EBITDA
$-4,358,117
Free Cash Flow
$2,499,097
Enterprise Value
$5,359,364
Total Cash
$6,956,822
Total Debt
$8,609
Shares Out
7,018,528
Trailing EPS
$1.78
Book Value
$0.76
ROE
-74.8%
ROA
-34.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 319,714 -2,747,037 -10,262,007 6,497,177 2,735,160 2,442,059 -3,748,853
Dec 2024 256,944 -1,006,340 -1,447,461 1,381,561 5,772,594 -4,391,034 -614,136
Dec 2023 415,940 -767,718 -719,920 1,421,251 7,506,423 -6,085,172 -563,983
Dec 2022 382,865 -1,104,183 -1,255,298 1,789,415 7,154,503 -5,365,088 -362,879

TTM Snapshot

Revenues TTM
$-1,976,740
NetIncome TTM
$-10,754,473
OpCashFlow TTM
—
Assets (Latest)
$9,176,362
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
LSTA LISATA THERAPEUTICS, INC. $11.24M $1.04 —
HEPA Hepion Pharmaceuticals, Inc. $10.38M $0.12 —
QNTM Quantum Biopharma Ltd. $10.22M $1.59 —
ASBP Aspire-Lakewood Holdings, Inc. $11.64M $8.30 —
CMMB Chemomab Therapeutics Ltd. $12.02M $1.64 —

News headlines (Yahoo Finance, 1h cache)

Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program
2026-11-16 13:32 · Yahoo
Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School
2026-10-26 12:00 · Yahoo
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
2026-10-05 12:00 · Yahoo
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
2026-08-25 12:00 · Yahoo
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
2026-07-01 12:00 · Yahoo
Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
2026-03-30 23:00 · Yahoo
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
2026-09-14 12:00 · Yahoo
We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate
2025-12-29 11:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.